110018 ⎘
dsDNA viruses; Details; Poxviridae; Orthopoxvirus, e.g. vaccinia virus, variola Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
SYNTHETIC CHIMERIC POXVIRUSES
#2Mammalian Cell Line for the Production of Modified Vaccinia Virus Ankara (MVA)
#3Use of Triplex CMV Vaccine in CAR T Cell Therapy
#4IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES
#5Poxvirus mRNA Vaccine and Use
#6SYNTHETIC CHIMERIC POXVIRUSES
#7HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF
#8POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF
#9RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY
#10SIGNAL SEQUENCES FOR NUCLEIC ACID VACCINES
#11ALUMINUM NANOCRYSTAL DELIVERY SYSTEM, AND SELF-ASSEMBLED PARTICLE ADJUVANT VACCINE BASED ON BINDING OF ALUMINUM NANOCRYSTAL DELIVERY SYSTEM AND VACCINE ANTIGEN MOLECULE
#12MULTIEPITOPE SELF-ASSEMBLED NANOPARTICLE VACCINE PLATFORM (MSN-VACCINE PLATFORM) AND USES THERE OF
#13Utilization of Micro-RNA for Downregulation of Cytotoxic Transgene Expression by Modified Vaccinia Virus Ankara (MVA)
#14HUMAN METAPNEUMOVIRUS COMBINATION VACCINE
#15SMALLPOX VACCINE FOR CANCER TREATMENT
#16FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS
#17FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS
#18Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an Immune Checkpoint Antagonist or Agonist
#19HBV VACCINE
#20Use of Triplex CMV Vaccine in CAR T Cell Therapy
#21ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19
#22Immuno-modulated replication-efficient Vaccinia virus strain
#23PERSONALIZED VACCINE
#24Recombinant Viral Vector, Immunogenic Composition Comprising Same, and Uses
#25Smallpox vaccine for cancer treatment
#26POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF
#27PROCESS FOR DESIGNING A RECOMBINANT POXVIRUS FOR A THERAPEUTIC VACCINE
#28IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES
#29Vaccinia viral vectors encoding chimeric virus like particles
#30BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING
#31SYNTHETIC CHIMERIC POXVIRUSES
#32USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS
#33Immunogen for broad-spectrum influenza vaccine and application thereof
#34Hepatitis C virus immunogenic compositions and methods of use thereof
#35Recombinant poxviruses for cancer immunotherapy
#36ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19
#37RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS
#38SYNTHETIC CHIMERIC VACCINIA VIRUS
#39Compositions and methods to enhance the immune system
#40Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine
#41Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor
#42Storage improved poxvirus compositions
#43FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS
#44Use of Triplex CMV Vaccine in CAR T Cell Therapy
#45Genetically modified recombinant vaccinia ankara (RMVA) vaccines of improved stability and methods of preparation thereof
#46Smallpox vaccine for cancer treatment
#47Immuno-modulated replication-efficient vaccinia virus strain
#48Vaccinia viral vectors encoding chimeric virus like particles
#49Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
#50Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
#51Stable virus-containing composition
#52Personalized vaccine
#53HBV VACCINE
#54Poxvirus-recombinants, compositions containing such recombinants, uses thereof, and methods of making and using the same
#55CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
#56P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof
#57Vaccinia virus vectors related to MVA with extensive genomic symmetries
#58Compositions and methods for generating an immune response to a tumor associated antigen
#59Recombinant vaccinia virus and use thereof
#60Hepatitis c virus immunogenic compositions and methods of use thereof
#61Recombinant HCMV and RHCMV vectors and uses thereof
#62IL-2 superagonists in combination with anti-PD-1 antibodies
#63Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity
#64Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine
#65MHC-bound peptide arrays and methods of use thereof
#66Smallpox vaccine for cancer treatment
#67Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof
#68Synthetic chimeric poxviruses
#69Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
#70Compositions and methods to enhance the immune system
#71DUCK EMBRYONIC DERIVED STEM CELL LINES FOR THE PRODUCTION OF VIRAL VACCINES
#72Whole expressed cell as antigen carrier, and use thereof in preparing vaccine or diagnostic agent, and screening monoclonal antibodies
#73Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
#74COMPOSITION AND USES THEREOF
#75RECOMBINANT PROTEINS OF PARAPOXVIRUS OVIS AND PHARMACEUTICAL COMPOSITIONS THEREFROM
#76VACCINE COMPOSITIONS AND METHODS OF USE TO TREAT NEONATAL SUBJECTS
#77Antigen delivery system
#78Compositions and methods to enhance the immune system
#79METHODS AND COMPOSITIONS TO PRODUCE VACCINES AGAINST SMALLPOX IN PLANTS
#80Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject
#81Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus
#82Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses
#83Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
#84Microorganisms for therapy
#85Compositions and methods for immunodominant antigens
#86RECOMBINANT POXVIRUS VECTOR COMPRISING TETANUS TOXIN FRAGMENT C
#87Compositions and methods to enhance the immune system
#88Smallpox vaccine for cancer treatment
#89BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING
#90Compositions and methods for immunodominant antigens of
#91Excipients for stabilising viral particles, polypeptides or biological material
#92Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
#93Method of making a virus using duck embryonic derived stem cell lines
#94Compositions and methods to enhance the immune system
#95Composition and uses thereof
#96Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein
#97Recombinant HCMV and RHCMV vectors and uses thereof
#98Recombinant vaccinia virus derived from KVAC103 strain
#99Attenuated vaccinia virus KVAC103 strain
#100Immune modulation
#101Single high dose of MVA induces a protective immune response in neonates and infants
#102Vector comprising multiple homologous nucleotide sequences
#103Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon
#104Immunogenic compositions comprising silicified virus and methods of use
#105METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
#106Production of viral vaccines in suspension on avian embryonic derived stem cell lines
#107Virus-containing formulation and use thereof
#108COMPOSITIONS, METHODS AND USES FOR POXVIRUS ELEMENTS IN VACCINE CONSTRUCTS
#109Poxviral vectors for low antibody response after a first priming immunization
#110Compositions and methods for immunodominant antigens of
#111Sequential and repeated immunization with four or more vector-based HIV gene vaccines
#112Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefrom
#113Inactivating pathogens with oxidizing agents for vaccine production
#114Vaccinia virus polypeptides
#115Compositions and methods to enhance the immune system
#116T-cell vaccination with viral vectors via mechanical epidermal disruption
#117Generation of duck cell lines
#118Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
#119Vaccinia virus polypeptides
#120Animal protein free media for cultivation of cells
#121Methods and compositions to produce vaccines against smallpox in plants
#122Modulation of immune responses by the poxviral K4 protein
#123Immediate protection against pathogens via MVA
#124Recombinant HCMV and RHCMV vectors and uses thereof
#125Compositions and methods for immunodominant antigens of
#126Compositions, methods and uses for expression of enterobacterium-associated peptides
#127Inactivating pathogens with oxidizing agents for vaccine production
#128Modified Vaccinia Ankara virus variant and cultivation method
#129Microorganisms for therapy
#130Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#131Production of viral vaccines in suspension on avian embryonic derived stem cell lines
#132MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCNATION OF NEONATES
#133Compositions and methods for immunodominant antigens of
#134Virus vaccination and treatment methods with OX40 agonist compositions
#135VACCINIA VIRUS POLYPEPTIDES
#136Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
#137Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
#138Microorganisms for therapy
#139Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#140T-cell vaccination with viral vectors via mechanical epidermal disruption
#141Compositions and methods for immunodominant antigens of
#142Vector comprising multiple homologous nucleotide sequences
#143Animal protein free media for cultivation of cells
#144Modified Vaccinia Ankara virus variant and cultivation method
#145METHOD FOR ENHANCING AN IMMUNE RESPONSE
#146Immediate protection against pathogens via MVA
#147Modified vaccinia virus ankara for the vaccination of neonates
#148Modified Vaccinia Virus Ankara for the vaccination of neonates
#149METHODS FOR GENERATING AN IMMUNE RESPONSE USING DNA AND A VIRAL VECTOR
#150Compositions and methods for preventing or treating a viral infection
#151Protein vaccines against poxviruses
#152RECOMBINANT MODIFIED VACCINIA VIRUS MEASLES VACCINE
#153Compositions and methods to enhance the immune system
#154Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#155treatment
#156Modified vaccinia ankara virus variant and cultivation method
#157Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents
#158Protein vaccines against poxviruses
#159Process for preparing live smallpox vaccine
#160Promoterless cassettes for expression of alpha virus structural proteins
#161Immediate protection against pathogens via MVA
#162Compositions and methods for immunodominant antigens
#163ADJUVANTED VACCINE
#164Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
#165DUCK EMBRYONIC DERIVED STEM CELL LINES FOR THE PRODUCTION OF VIRAL VACCINES
#166Microorganisms for therapy
#167Modified vaccinia virus ankara for the vaccination of neonates
#168Compositions, methods and kits relating to poxvirus subunit vaccines
#169Microorganisms for therapy
#170Smallpox DNA vaccine and the antigens therein that elicit an immune response
#171Compositions and methods for immunodominant antigens of
#172Modified vaccinia virus ankara for the vaccination of neonates
#173Production of viral vaccines in suspension on avian embryonic derived stem cell lines
#174Promoterless cassettes for expression of alphavirus structural proteins
#175DNA immunogenic composition comprising a full-length modified poxvirus L1R gene fused to a tPA leader sequence
#176COMPOSITIONS AND METHODS FOR ORTHOPOX VIRUS VACCINATION
#177Poxvirus methods and compositions
#178Modified vaccinia ankara virus variant and cultivation method
#179Modified vaccinia ankara virus variant and cultivation method
#180Compositions and methods for preventing or treating a viral infection
#181Method for treatment of HIV infection
#182Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#183Compositions and methods for orthopox virus vaccination
#184Composition and Method for Inducing Protective Vaccine Response Using SDF-1
#185Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
#186Peptide originating from vaccinia virus
#187Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
#188Microorganisms for therapy
#189Microorganisms for therapy
#190Composition and method for inducing protective vaccine response
#191Compositions and methods for generating an immune response
#192Inactivating pathogens with oxidizing agents for vaccine production
#193Microorganisms for therapy
#194Vaccines
#195Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
#196Vaccinia virus nucleic acids, polypeptides and immunogenic compositions
#197Method for treatment of HIV infection
#198Modified Vaccinia virus Ankara for the vaccination of neonates
#199Viral vectors having reduced virulence
#200Compositions, methods and kits relating to poxvirus subunit vaccines
#201Microorganisms for therapy
#202Modified vaccinia virus ankara for the vaccination of neonates
#203Modified Vaccinia Ankara virus variant and cultivation method
#204Recombinant poxvirus not having a functional 3beta-hsd gene
#205Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
#206Viral vectors having reduced virulence
#207Microorganisms for therapy